TMT212

DRUG6 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumorsChildren and Adolescents with Cancers Harboring V600 mutation.Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - AdenocarcinomaDifferent types of advanced cancerMultiple indicationsPreviously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

Phase 1

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

CompletedNCT02900664

Novartis PharmaceuticalsColorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

Start: 2016-08-23End: 2021-03-17Updated: 2022-03-29

KontRASt-03: A Phase Ib/II, multicenter, open-label platform study of JDQ443 with select combinations in patients with advanced solid tumors harboring the KRAS G12C mutation

RecruitingCTIS2023-506716-41-00

Novartis Pharma AGAdult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors

Start: 2023-05-08Target: 200Updated: 2026-01-19

An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments

Active, not recruitingCTIS2023-508841-42-00

Novartis Pharma AGDifferent types of advanced cancer

Start: 2019-10-30Target: 75Updated: 2025-10-28

Phase 2

A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

Active, not recruitingCTIS2024-511934-11-00

Novartis Pharma AGPreviously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

Start: 2021-04-27Target: 53Updated: 2025-12-11

Phase 4

An open label, multi-center roll-over study to assess longterm effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib)

Active, not recruitingCTIS2023-509276-42-00

Novartis Pharma AGChildren and Adolescents with Cancers Harboring V600 mutation.

Start: 2019-10-30Target: 68Updated: 2025-12-22

An open label, multi-center roll-over study to assess long-term safety in patients who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (trametinib) study and are judged by the investigator to benefit from continued treatment.

RecruitingCTIS2023-509318-13-00

Novartis Pharma AGMultiple indications

Start: 2018-01-15Target: 17Updated: 2025-08-01